Achieve Life Sciences Data Shows Cytisinicline Effective in Hard-to-Treat Smokers
Event summary
- Achieve Life Sciences presented data at SRNT 2026 showing cytisinicline achieved high quit rates in smokers with extensive prior treatment exposure.
- Pooled Phase 3 analysis of 1,602 participants demonstrated efficacy regardless of prior quit attempts or medication use.
- Late-breaking survey data from ORCA-OL study highlighted positive participant experiences with extended cytisinicline use.
- FDA review of cytisinicline NDA ongoing with PDUFA date set for June 20, 2026.
The big picture
Achieve's data suggests cytisinicline could address a significant unmet need in smoking cessation, particularly for patients who have failed other treatments. The FDA's decision in June 2026 will be critical for Achieve's commercial prospects in a market dominated by varenicline and nicotine replacement therapies. The company's focus on both smoking and vaping cessation positions it to capitalize on growing regulatory interest in nicotine addiction treatments.
What we're watching
- Regulatory Approval
- Whether the FDA will approve cytisinicline by the June 20, 2026 PDUFA date.
- Market Differentiation
- How Achieve positions cytisinicline against existing smoking cessation treatments.
- Commercialization Strategy
- The pace at which Achieve can scale cytisinicline's commercialization post-approval.
Related topics